Source: http://www.wildy.com/isbn/9780231540070/fda-in-the-twenty-first-century-the-challenges-of-regulating-drugs-and-new-technologies-ebook-columbia-university-press
Timestamp: 2017-06-27 02:06:06
Document Index: 612546135

Matched Legal Cases: ['art 1', 'art 2', 'art 3', 'art 4', 'art 5', 'art 6', 'art 7']

Wildy & Sons Ltd — The World’s Legal Bookshop Search Results for isbn: '9780231540070'
Fda in the Twenty-First Century: The Challenges of Regulating Drugs and New Technologies (eBook)
Edited by: Holly Fernandez Lynch, I. Glenn Cohen
ISBN13: 9780231540070
(ePub) Price: £55.99 + £11.20 VAT
Hardback 9780231171182
Today, these challenges are compounded by the pressures of globalization, the introduction of novel technologies, and fast-evolving threats to public health. With essays by leading scholars and government and private-industry experts, FDA in the Twenty-First Century addresses perennial and new problems and the improvements the agency can make to better serve the public good. The collection features essays on effective regulation in an era of globalization, consumer empowerment, and comparative effectiveness, as well as questions of data transparency, conflicts of interest, industry responsibility, and innovation policy, all with an emphasis on pharmaceuticals. The book also intervenes in the debate over off-label drug marketing and the proper role of the FDA before and after a drug goes on the market. Dealing honestly and thoroughly with the FDA's successes and failures, these essays rethink the structure, function, and future of the agency and the effect policy innovations may have on regulatory institutions abroad. Subjects: Medical Law, eBooks
Contents: AcknowledgmentsIntroduction, by Holly Fernandez Lynch and I. Glenn Cohen1. Historical Themes and Developments at FDA Over the Past Fifty Years, by Peter Barton HuttPart 1. FDA in a Changing WorldIntroduction, by Holly Fernandez Lynch2. A Global and Innovative Regulatory Environment for the U.S. FDA, by Howard Sklamberg and Jennifer Devine3. FDA and the Rise of the Empowered Patient, by Lewis A. Grossman4. After the FDA: A Twentieth-Century Agency in a Postmodern World, by Theodore W. Ruger5. The Future of Prospective Medicine Under the Food and Drug Administration Amendments Act of 2007, by Barbara J. EvansPart 2. Preserving Public Trust and Demanding AccountabilityIntroduction, by Christopher Robertson6. Global Trends Toward Transparency in Participant-Level Clinical Trials Data, by Alla Digilova, Rebecca Li, Mark Barnes, and Barbara Bierer7. Conflicts of Interest in FDA Advisory Committees: The Paradox of Multiple Financial Ties, by Genevieve Pham-Kanter8. The Crime of Being in Charge: Executive Culpability and Collateral Consequences, by Katrice Bridges Copeland9. Recalibrating Enforcement in the Biomedical Industry: Deterrence and the Primacy of Protecting the Public Health, by Patrick O'LearyPart 3. Protecting the Public Within Constitutional LimitsIntroduction, by Glenn Cohen10. Prospects for Regulation of Off-Label Drug Promotion in an Era of Expanding Commercial Speech Protection, by Aaron S. Kesselheim and Michelle M. Mello11. The FDCA as the Test for Truth of Promotional Claims, by Christopher Robertson12. Why FDA's Ban on Off-Label Promotion Violates the First Amendment: A Study in the Values of Commercial Speech Protection, by Coleen Klasmeier and Martin H. RedishPart 4. Timing Is Everything: Balancing Access and UncertaintyIntroduction, by W. Nicholson Price II13. Speed Versus Safety in Drug Development, by R. Alta Charo14. Overcoming "Premarket Syndrome": Promoting Better Postmarket Surveillance in an Evolving Drug Development Context, by Shannon Gibson and Trudo Lemmens15. FDA's Public Health Imperative: An Increased Role for Active Postmarket Analysis, by Efthimios ParasidisPart 5. Old and New Issues in Drug RegulationIntroduction, by R. Alta Charo16. The Drug Efficacy Study and Its Manifold Legacies, by Daniel Carpenter, Jeremy Greene, and Susan Moffitt17. Drug Safety Communication: The Evolving Environment, by Geoffrey Levitt18. Innovation Policy Failures in the Manufacturing of Drugs, by W. Nicholson Price IIPart 6. Regulatory Exclusivities and the Regulation of Generic Drugs and BiosimilarsIntroduction, by Benjamin N. Roin19. From "Recycled Molecule" to Orphan Drug: Lessons from Makena, by Kate Greenwood20. FDA, Negotiated Rule Making, and Generics: A Proposal, by Marie Boyd21. The "Follow-On" Challenge: Statutory Exclusivities and Patent Dances, by Arti Rai22. FDA Regulation of Biosimilars, by Henry Grabowski and Erika LietzanPart 7. New Wine in Old Bottles: FDA's Role in Regulating New TechnologiesIntroduction, by Frances H. Miller23. Analog Agency in a Digital World, by Nathan Cortez24. Twenty-First-Century Technology with Twentieth-Century Baggage: FDA Regulation of Regenerative Medicine, by Margaret Foster Riley25. Device-ive Maneuvers: FDA's Risk Assessment of Bifurcated Direct-to-Consumer Genetic Testing, by Elizabeth R. Pike and Kayte Spector-Bagdady26. A New Regulatory Function for E-Prescriptions: Linking FDA to Physicians and Patient Records, by Andrew English, David Rosenberg, and Huaou Yan27. Race and the FDA, by Jonathan KahnContributorsIndex